A review of tasquinimod in the treatment of advanced prostate cancer

review of tasquinimod in the treatment of advanced prostate cancer Review (18) Total Article Views Authors: Williamson SC, Hartley AE, Heer R Published Date March 2013 Volume 2013:7 Pages 167 - 174 DOI: http://dx.doi.org/10.2147/DDDT.S31500 Received: 20 December 2012 Accepted: 06 February 2013 Published: 21 March 2013 Stuart Charles Williamson, Alice Elizabeth Hartley, Rakesh Heer Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK Abstract: Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival. Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.